Publication

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2

Related publications (77)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2

Graph Chatbot

Chat with Graph Search

Synthesis of DNA‐encoded disulfide‐ and thioether‐cyclized peptides

From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

Synthesis of asparagusic acid modified lysine and its application in solid-phase synthesis of peptides with enhanced cellular uptake

Development of an albumin-binding ligand for prolonging the plasma half-life of peptide therapeutics

New methods for developing (bi)cyclic peptides by phage display

Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity

Phage Selection of Cyclic Peptides for Application in Research and Drug Development

Scanning tunneling microscopy on large bio-molecular systems on surfaces

Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides

Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity